Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Receivables - Net (2022 - 2025)

Historic Receivables - Net for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $52000.0.

  • Orchestra BioMed Holdings' Receivables - Net fell 5478.26% to $52000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $52000.0, marking a year-over-year decrease of 5478.26%. This contributed to the annual value of $92000.0 for FY2024, which is 707.07% down from last year.
  • As of Q3 2025, Orchestra BioMed Holdings' Receivables - Net stood at $52000.0, which was down 5478.26% from $83000.0 recorded in Q2 2025.
  • Orchestra BioMed Holdings' Receivables - Net's 5-year high stood at $171000.0 during Q2 2023, with a 5-year trough of $52000.0 in Q3 2025.
  • Over the past 4 years, Orchestra BioMed Holdings' median Receivables - Net value was $87500.0 (recorded in 2023), while the average stood at $92166.7.
  • Per our database at Business Quant, Orchestra BioMed Holdings' Receivables - Net soared by 3372.09% in 2024 and then crashed by 5478.26% in 2025.
  • Orchestra BioMed Holdings' Receivables - Net (Quarter) stood at $96000.0 in 2022, then rose by 3.12% to $99000.0 in 2023, then fell by 7.07% to $92000.0 in 2024, then crashed by 43.48% to $52000.0 in 2025.
  • Its Receivables - Net stands at $52000.0 for Q3 2025, versus $83000.0 for Q2 2025 and $89000.0 for Q1 2025.